← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,625	+50	+2%	$176B
2	2 Danaher DHR $158B	2,321	+42	+2%	$131B
3	3 Novartis NVS $279B	1,342	+29	+2%	$12.7B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,321	-71	-5%	$66.7B
5	5 Agilent Technologies A $49.1B	1,082	+30	+3%	$34B
6	6 Illumina ILMN $41B	854	+48	+6%	$20.6B
7	7 Charles River Laboratories CRL $14.4B	638	+9	+1%	$9.78B
8	8 Alnylam Pharmaceuticals ALNY $30B	595	+28	+5%	$30.1B
9	9 Revvity RVTY $17B	531	+4	+0.8%	$12.4B
10	10 Sarepta Therapeutics SRPT $1.78B	465	+7	+2%	$10.7B
11	11 CRISPR Therapeutics CRSP $4.86B	406	-10	-2%	$2.54B
12	12 Bruker BRKR $8.47B	367	0	0%	$7.19B
13	13 Ionis Pharmaceuticals IONS $7.1B	355	+1	+0.3%	$5.61B
14	14 GRAIL Inc GRAL $6.24B	333	+22	+7%	$477M
15	15 Qiagen QGEN $9.41B	326	-5	-2%	$6.6B
16	16 Veracyte VCYT $3.5B	318	+26	+9%	$3.25B
17	17 Ultragenyx Pharmaceutical RARE $1.47B	313	+12	+4%	$3.68B
18	18 Azenta AZTA $1.63B	311	-2	-0.6%	$2.62B
19	19 Guardant Health GH $21.9B	298	+27	+10%	$3.65B
20	20 Intellia Therapeutics NTLA $1.6B	296	+12	+4%	$1.16B
21	21 Vericel Corp VCEL $2.06B	279	+11	+4%	$2.87B
22	22 10x Genomics TXG $9.52B	273	+7	+3%	$1.5B
23	23 Arrowhead Research ARWR $8.25B	269	-2	-0.7%	$1.88B
24	24 Krystal Biotech KRYS $9.79B	264	-19	-7%	$4.35B
25	25 BridgeBio Pharma BBIO $12.7B	263	+10	+4%	$4.85B